Targets › RPLB
2 programs from 1 company in 2 trials: 2 Phase 2; Infectious disease.
Open in Phaseline: the race on RPLB, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| Assistance Publique - Hôpitaux de Paris | Linezolid Bacterial 70S ribosome inhibitor | RPLB | Phase 2 | Tuberculosis | – |
| Assistance Publique - Hôpitaux de Paris | Tedizolid Bacterial 70S ribosome inhibitor | RPLB | Phase 2 | Tuberculosis | – |
Tuberculosis (2)
small molecule (2)
Assistance Publique - Hôpitaux de Paris (2)
–
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.